Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study

BACKGROUND: Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, C., Martin, C., Winter, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429539/
https://www.ncbi.nlm.nih.gov/pubmed/30937280
http://dx.doi.org/10.1016/j.jbo.2019.100226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429539/
https://www.ncbi.nlm.nih.gov/pubmed/30937280
http://dx.doi.org/10.1016/j.jbo.2019.100226

Ejemplares similares